Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries

Lack of Efficacy of Tai Chi in Improving Quality of Life in Breast Cancer Survivors: a Systematic Review and Meta-analysis

“…In the last decades, the number of breast cancer cases has steadily increased, especially in low and middle income countries (Pedraza et al, 2012;Anaya-Ruiz et al, 2014). At present, breast cancer is generally treated with the possible medical treatment, i.e., a multidisciplinary approach is preferable (Saini et al, 2012). However, some studies found that older breast cancer survivors (BCS) showed multiple indications of decrements in their health-related quality of life (QoL), and bone mineral density (BMD) (Yusuf et al, 2013;Erdogan et al, 2014).…”

Multidisciplinary care team for cancer patients and its implementation in several Middle Eastern countries

“…In Belgium, France and the Netherlands, the use of MDTs is mandatory [21][22][23]. The UK, Canada and Australia all have national or state-defined guidelines for the use of MDTs in cancer care [1,18,19].…”

MicroRNA-711 is a prognostic factor for poor overall survival and has an oncogenic role in breast cancer

“…Primary treatments include surgery, radiotherapy, chemotherapy, endocrine therapy and targeted therapy. Studies have shown that the integrated use of a variety of treatments is advantageous to the prognosis of breast cancer patients (6). At present, formulation of a treatment plan, including surgery and adjuvant therapy, is primarily based on clinical stage and the presence of several limited biomarkers, including estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 (6).…”

“…Studies have shown that the integrated use of a variety of treatments is advantageous to the prognosis of breast cancer patients (6). At present, formulation of a treatment plan, including surgery and adjuvant therapy, is primarily based on clinical stage and the presence of several limited biomarkers, including estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 (6). However, the tumor-node-metastasis staging system and these biomarkers do not meet the requirements for personalized therapy and/or precise therapy.…”

“…miRNA expression is usually dysregulated in various cancer types (15,16), including breast cancer (17). miRNAs specifically bind to the 3'-untranslated region of target mRNAs, which results in the degradation of MicroRNA-711 is a prognostic factor for poor overall survival and has an oncogenic role in breast cancer , XIAO-FENG STEVEN ZHENG 5 , YIBIN KANG 6 and HUI-YUN WANG the mRNA or inhibition of its translation (18). In addition, miRNAs may be capable of affecting the transcription of target genes through promoter activation (19) or transcriptional silencing (20).…”